WSG ADAPT (HR +ve/Her-2 Negative) Clinical Trial– results showed subgroup of patients with low tumor burden and low post operative KI67 levels can be good candidates for de-escalation of chemotherapy.
GIM 2 Clinical trial: confirmed utility of dose dense chemotherapy as preferred adjuvant treatment in patients with node +ve Early Breast Cancer.
Keynote 522 Clinical Trial PRO data: measured using EORTC QLQ-30 &QLQ-BR23 questionnaire showed no detrimental with addition of Pembrolizumab to neoadjuvant Chemotherapy in Triple Negative Early Breast Cancer
Monarch 3 Study: Showing significant long terms PFS benefit & also reported chemotherapy free survival of 46 months for Abemaciclib + Non-Steroidal Aromatase Inhibitor.
TROPICS 02 Study: confirmed utility of Sacituzumab in HR+ve -Her2 Negative MBC patients in 3rd line beyond with better OS compared to Treatment of Physicians Choice (TPC).
Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
